Want to see HK:6896 full AI Analyst Report?
Top Page
Golden Throat Holdings Group Co Ltd
(6896)
Select Model
Select Model
Rating:64Neutral
Price Target:
HK$2.50
â–¼(-18.57% Downside)
Action:Reiterated
Date:08/25/26
The score is driven primarily by mixed fundamentals: strong structural margins are offset by a sharp 2025 cash-flow decline, softer revenue, and higher leverage. Technicals are notably bearish with broad weakness versus key moving averages and negative momentum. Valuation is a major positive, supported by a low P/E and very high dividend yield.
Positive Factors
Sustained High Profitability
Persistently high gross and net margins indicate pricing power, brand-supported demand, and effective cost control. This profitability provides a durable earnings cushion and can help fund operations even when revenue growth is uneven.
Negative Factors
Declining Revenue and Earnings Growth
Recent top-line contraction and weaker earnings growth indicate inconsistent demand or execution. If this pattern persists, it could reduce operating leverage, constrain reinvestment, and weaken the company’s ability to sustain historical profitability.
Read all positive and negative factors
Positive Factors
Negative Factors
Sustained High Profitability
Persistently high gross and net margins indicate pricing power, brand-supported demand, and effective cost control. This profitability provides a durable earnings cushion and can help fund operations even when revenue growth is uneven.
Read all positive factors
Golden Throat Holdings Group Co Ltd (6896) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$1.63B
Dividend Yield15.89%
Average Volume (3M)770.57K
Price to Earnings (P/E)6.4
Beta (1Y)0.13
Revenue Growth-5.37%
EPS Growth-18.03%
CountryHK
Employees840
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)0.33
Shares Outstanding739,302,000
10 Day Avg. Volume459,548
30 Day Avg. Volume770,573
Financial Highlights & Ratios
PEG Ratio-0.38
Price to Book (P/B)1.47
Price to Sales (P/S)2.15
P/FCF Ratio25.97
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Golden Throat Holdings Group Co Ltd Business Overview & Revenue Model
Company Description
Golden Throat Holdings Group Company Limited operates as an investment holding entity primarily engaged in the production and distribution of pharmaceutical goods, health-focused foods, and various other products within the People's Republic of Ch...
How the Company Makes Money
Golden Throat Holdings Group Co Ltd makes money primarily by selling branded throat lozenges (and any related products within its portfolio) to wholesalers, distributors, and retailers, who then sell to end consumers. The company’s core revenue st...
Golden Throat Holdings Group Co Ltd Financial Statement Overview
Summary
Income Statement
78
Positive
Balance Sheet
70
Positive
Cash Flow
48
Neutral
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 943.26M | 1.19B | 961.38M | 992.01M | 820.54M |
| Gross Profit | 717.01M | 894.18M | 697.72M | 720.92M | 577.74M |
| EBITDA | 337.06M | 456.65M | 410.75M | 424.93M | 281.80M |
| Net Income | 251.20M | 318.63M | 250.16M | 281.22M | 187.64M |
Balance Sheet | |||||
| Total Assets | 2.29B | 2.25B | 2.30B | 2.30B | 1.95B |
| Cash, Cash Equivalents and Short-Term Investments | 1.08B | 1.14B | 1.07B | 925.51M | 802.84M |
| Total Debt | 584.52M | 426.92M | 412.34M | 272.59M | 235.00M |
| Total Liabilities | 912.77M | 784.87M | 748.34M | 760.18M | 588.04M |
| Stockholders Equity | 1.38B | 1.47B | 1.55B | 1.54B | 1.37B |
Cash Flow | |||||
| Free Cash Flow | 77.99M | 408.65M | 221.30M | 255.30M | 116.23M |
| Operating Cash Flow | 123.31M | 475.87M | 238.84M | 271.15M | 164.89M |
| Investing Cash Flow | -55.02M | -41.60M | -59.67M | 36.59M | -145.11M |
| Financing Cash Flow | -228.90M | -335.18M | -79.38M | -142.01M | -10.21M |
Golden Throat Holdings Group Co Ltd Technical Analysis
Negative
3.07
Price Trends
2.93
Negative
3.04
Negative
3.00
Negative
Market Momentum
-0.24
Positive
24.66
Positive
19.34
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:6896, the sentiment is Negative. The current price of 3.07 is above the 20-day moving average (MA) of 2.61, above the 50-day MA of 2.93, and above the 200-day MA of 3.00, indicating a bearish trend. The MACD of -0.24 indicates Positive momentum. The RSI at 24.66 is Positive, neither overbought nor oversold. The STOCH value of 19.34 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:6896.
Golden Throat Holdings Group Co Ltd Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
77 Outperform | HK$779.10M | 7.75 | 13.59% | 7.40% | 10.63% | 39.44% | |
77 Outperform | HK$1.86B | 6.39 | 13.26% | 9.37% | -0.47% | -0.40% | |
64 Neutral | HK$1.63B | 6.43 | 16.70% | 15.89% | -5.37% | -18.03% | |
53 Neutral | HK$6.72B | -5.43 | -4.98% | 0.26% | -15.80% | -298.94% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | HK$345.46M | 86.11 | 0.34% | 84.69% | -8.30% | -44.44% | |
43 Neutral | HK$139.08M | -4.57 | -21.66% | 0.48% | -6.71% | 43.14% |
* Healthcare Sector Average
HK:6896
Golden Throat Holdings Group Co Ltd
2.14
-1.03
-32.41%
HK:0570
China Traditional Chinese Medicine Holdings Co
1.31
-0.85
-39.35%
HK:0897
Wai Yuen Tong Medicine Holdings Limited
0.31
-0.05
-13.89%
HK:1498
PuraPharm Corp. Ltd.
0.26
-0.19
-42.22%
HK:0239
Pak Fah Yeow International Limited
2.48
0.17
7.27%
HK:2633
Jacobson Pharma Corporation Limited
0.97
-0.43
-30.87%
Golden Throat Holdings Group Co Ltd Corporate Events
Golden Throat Warns of 43% Interim Profit Drop Amid Higher Promotional Spend
Aug 20, 2026
Golden Throat Holdings Group Company Limited, a Hong Kong-listed consumer healthcare group known for its throat products and operating mainly in Guangxi, China, has been intensifying promotional efforts to strengthen its market presence. These ini...
Golden Throat Sets Board Meeting to Approve Interim Results and Consider Dividend
Aug 19, 2026
Golden Throat Holdings Group Company Limited has scheduled a board meeting for 31 August 2026 to review and approve the interim results for the six months ended 30 June 2026, along with their publication. The board will also consider the declarati...
Golden Throat Wins Strong Shareholder Backing for Dividend, Mandates and Governance Changes
Jun 5, 2026
Golden Throat Holdings Group Co Ltd reported that all resolutions at its 5 June 2026 annual general meeting were approved by shareholders via poll, with full board attendance and no voting restrictions or abstentions required under Hong Kong listi...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.